Amid growing domestic pressure — partly from a business lobby attracted by short-term gains — to reset India's China policy in response to the Trump administration's transactional shifts, the author argues that strategic patience and internal economic fortification, rather than bloc-dependence or hasty accommodation of Beijing, is the correct path for New Delhi.

A section of India's business community argues that the post-2020 confrontational posture toward China was shaped more by Washington's containment logic than by India's own economic interests, and that continued antagonism costs India more than it costs China.

• API dependency: India imports approximately 65–70% of its Active Pharmaceutical Ingredients from China — a structural dependency built over two decades of trade liberalisation.
• Post-Galwan restrictions: After the Galwan clashes (June 2020), India amended FDI rules to require government approval for investments from land-border-sharing countries (Press Note 3, 2020) and banned over 300 Chinese mobile applications under Section 69A of the IT Act.
• The lobby's argument: Cheap Chinese capital, machinery, and APIs are structurally indispensable for India's manufacturing ambitions (including PLI-scheme targets); restricting them raises input costs, fuels inflation, and slows industrial growth without materially weakening China.

• Depsang (2013): PLA troops intruded ~19 km into Indian-claimed territory in Western Ladakh; 21-day standoff resolved without formal settlement of patrol point access (PP 10–13 remains contested).
• Chumar (2014): PLA intrusion coincided with Xi Jinping's state visit to India — a calibrated diplomatic signal.
• Doklam (2017): PLA road construction in Bhutan's claimed territory (adjacent to the Siliguri Corridor). India intervened militarily on Bhutan's behalf; 73-day standoff resolved by mutual withdrawal without formal settlement.
• Galwan Valley (2020): Most lethal LAC incident since 1967; 20 Indian Army personnel killed. Led to India's economic restrictions and accelerated Quad engagement.
• Arunachal Pradesh renaming: China periodically renames geographical features in Arunachal Pradesh ("Zangnan"), which it claims as "South Tibet" — an assertion of sovereignty over Indian-administered territory.
• Stapled visas: China has issued stapled (non-stamped) visas to residents of Jammu & Kashmir and Arunachal Pradesh, implicitly contesting India's sovereignty.
• UNSC veto use: China has used its UNSC veto to shield Pakistan-based terrorist entities from international sanctions (e.g., Masood Azhar, blocked repeatedly before 2019 listing). China also blocks India's UNSC permanent membership and NSG entry.
• Operation Sindoor (May 2025): The article alleges China provided Islamabad real-time tactical satellite intelligence during India's military strikes — if accurate, a qualitative shift from arms supplier to active participant in Pakistan's security architecture against India.

• The leverage argument: India's post-Galwan restrictions — app bans, FDI review, Huawei/ZTE telecom exclusion — are diplomatic cost-imposition signals. Removing them without Chinese concessions would be unilateral economic disarmament.
• The "economic kill-switch" risk: Structural dependence on Chinese inputs (APIs, rare earths, electronics) gives Beijing a coercive instrument — the ability to disrupt Indian industry by withholding critical components, as demonstrated against other countries.
• China's power doctrine: A core realist argument — China respects demonstrated capability and exploits perceived vulnerability. Signalling inability to sustain economic pressure may encourage rather than deter Chinese border assertiveness.
• The $100 billion trade deficit: Resuming unrestricted Chinese market access without border resolution expands a structural deficit that, in the author's view, already finances India's encirclement through China's infrastructure presence in South Asia (CPEC, Hambantota).

• Supply chain resilience: Accelerate domestic manufacturing of APIs, electronics, and critical inputs — even at short-term cost — to reduce structural vulnerability.
• Trade diversification: Expand partnerships across Europe, East Asia (Japan, South Korea, Vietnam) and the Global South to reduce bilateral China dependence.
• Preserve economic leverage: Post-Galwan restrictions are diplomatic instruments, not merely reactive measures — do not dilute them without reciprocal Chinese concessions on the border.
• Strategic patience: Avoid hasty decisions driven by either Washington anxiety or business lobby pressure; the border dispute is generational and demands a long-horizon framework.

• The realist logic is analytically consistent and grounded in India's experience of Chinese coercion. Asymmetric economic interdependence creating political vulnerability is well-established in IR literature.
• The manufacturing alternative is easier prescribed than executed. India's PLI schemes have shown mixed results; API domestic manufacturing investment has been slow; solar panel manufacturing remains cost-uncompetitive without Chinese inputs.
• The article underweights the fiscal cost of sustained estrangement. Bilateral restriction has raised Indian input costs and slowed electronics manufacturing growth — a real trade-off the article does not fully acknowledge.
• Multi-alignment remains structurally sound as India's foreign policy doctrine, though it requires continuous calibration — the author's "walk straight" framing captures this accurately.

A global Lancet Public Health study reveals that India uses 18.3 defined daily doses of antibiotics per 1,000 people per day — nearly double the optimal range of 9.9–14.7 — with an over-reliance on broad-spectrum "Watch" antibiotics and a significant underuse of first-line "Access" antibiotics; the editorial argues that evidence-based prescribing and stronger stewardship mechanisms must underpin India's AMR response.

Figure 3 — How Antibiotic Resistance Occurs: The Mechanism

The four-step mechanism of antibiotic resistance development — from natural resistant variants surviving antibiotic treatment to resistant bacteria multiplying and transferring resistance genes horizontally. Image: Public Health England / BBC; reproduced with credit for educational use.

• Optimal range: 9.9–14.7 defined daily doses (DDD) per 1,000 people per day
• Actual use: 18.3 DDD/1,000/day — significantly above the upper optimal threshold
• Watch antibiotics: Actual 9.3 DDD vs. recommended 6 DDD — a 55% excess, indicating systemic over-prescription of broad-spectrum drugs
• Access antibiotics: Actual 4.5 DDD — well below what first-line treatment coverage requires
• The paradox: India simultaneously over-uses broad-spectrum antibiotics and under-provides first-line drugs — consistent with fragmented care, poor diagnostics, and irrational prescribing rather than a single linear failure

• Healthcare system pressure: Overstretched physicians in public facilities, time-constrained consultations, and patient expectations of immediate symptomatic relief create incentives for broad-spectrum prescriptions over accurate diagnosis-first approaches.
• Diagnostic access gap: Rapid diagnostic tests, culture-and-sensitivity testing, and microbiological infrastructure are inadequate at secondary and primary care levels; prescribers resort to empirical broad-spectrum therapy in the absence of reliable pathogen identification.
• Over-the-counter sale: Despite Schedule H1 (2013), antibiotics are widely available without prescription at pharmacies — an enforcement failure rather than a regulatory design gap.
• Irrational FDCs: Fixed-dose combinations combining antibiotics without pharmacological rationale inflate Watch and Reserve consumption and obscure dosage clarity.
• Agriculture and livestock: Colistin — a critical Reserve antibiotic — was used as a livestock growth promoter until a 2019 ban; implementation remains inconsistent.
• Environmental AMR: Pharmaceutical manufacturing effluents (notably Hyderabad's bulk drug hub) carry antibiotic residues into water bodies, selecting for AMR genes in environmental bacteria that re-enter human populations through water and food chains.

• India's National Action Plan on AMR (NAP-AMR) 2017–21 operated under the One Health framework aligned with WHO's Global Action Plan on AMR (2015). NAP-AMR 2.0 (2025–2029) is the current iteration.
• Core pillars: Antimicrobial stewardship in human health; infection prevention and control; surveillance (ICMR-AMR network); rational use in animal health; environmental action; research and innovation.
• Antimicrobial Stewardship Programmes (ASPs): Hospital-based multidisciplinary programmes optimising antibiotic selection, dosage and duration — now mandatory in NABH-accredited hospitals.
• Red Line Campaign: Awareness tool discouraging self-medication with prescription antibiotics marked with a red line on packaging.
• The editorial's core prescriptions: Stricter enforcement of prescription-only regulations; eliminating irrational FDCs; coordinated pharmaceutical supply chain compliance; strengthening diagnostics to enable targeted therapy.

• The editorial is analytically sound in identifying the structural — rather than individual — nature of India's AMR problem: diagnostic gaps, enforcement failures, and supply-chain incentives sustain irrational prescribing as a system property, not merely as individual physician error.
• One Health dimensions are underaddressed: The editorial focuses primarily on human health prescribing; livestock and environmental AMR — arguably India's largest AMR reservoirs — receive brief mention but are not developed.
• Enforcement versus regulation: India has adequate AMR regulations in many areas; the core failure is implementation capacity — a governance challenge requiring institutional investment, not only policy design.
• Access antibiotic underuse has a supply-side explanation: First-line drugs may be unavailable or unaffordable in public health facilities, driving physicians and patients toward private pharmacies and broader-spectrum alternatives.